In 2024, a plasma phosphorylated tau 217 immunoassay demonstrated high diagnostic accuracy for Alzheimer disease pathology across three observational cohorts, underscoring its potential as a reliable biomarker and shedding light on the underlying pathophysiology of tau protein dysregulation.